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Abstract
Leptomeningeal metastases (LM) currently lack standardization with respect to response assessment. A Response 
Assessment in Neuro-Oncology (RANO) working group with expertise in LM developed a consensus proposal for 
evaluating patients treated for this disease. Three basic elements in assessing response in LM are proposed: a 
standardized neurological examination, cerebral spinal fluid (CSF) cytology or flow cytometry, and radiographic 
evaluation. The group recommends that all patients enrolling in clinical trials undergo CSF analysis (cytology in all 
cancers; flow cytometry in hematologic cancers), complete contrast-enhanced neuraxis MRI, and in instances of 
planned intra-CSF therapy, radioisotope CSF flow studies. In conjunction with the RANO Neurological Assessment 
working group, a standardized instrument was created for assessing the neurological exam in patients with LM. 
Considering that most lesions in LM are nonmeasurable and that assessment of neuroimaging in LM is subjective, 
neuroimaging is graded as stable, progressive, or improved using a novel radiological LM response scorecard. 
Radiographic disease progression in isolation (ie, negative CSF cytology/flow cytometry and stable neurological 
assessment) would be defined as LM disease progression. The RANO LM working group has proposed a method of 
response evaluation for patients with LM that will require further testing, validation, and likely refinement with use.
Key words:
CSF cytology/flow cytometry | leptomeningeal metastasis |  
neurological examination | neuraxis MRI.
In a previous article, the authors critically reanalyzed rand-
omized controlled trials (RCT) conducted in leptomeningeal 
metastases (LM) as well as discussed controversies in the 
treatment of LM.1 The purpose of the current article is to 
propose new response criteria for LM as part of a Response 
Assessment in Neuro-Oncology (RANO) working group 
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initiative. The goal of the proposed response criteria is to 
standardize assessment of treatment of patients with LM 
in clinical trials, which would be of practical use outside of 
clinical trials. Three elements of treatment response in LM 
are universally recognized: the neurological examination, 
the cerebral spinal fluid (CSF) cytology or flow cytometry 
(FC) evaluation for the presence or absence of circulating 
tumor cells, and CNS imaging. Consequently, the RANO 
LM working group recommends that all patients enrolling 
in LM clinical trials undergo a complete standardized neu-
rological examination (Table 1), CSF analysis (including 
cytology in all cancers and FC in hematologic cancers), 
complete contrast-enhanced neuraxis (brain and spine) 
MRI, and radioisotope CSF flow studies (only in patients 
treated with intra-CSF therapy) at prespecified times. The 
majority of RCT in LM patients have utilized a combina-
tion of neurological examination and CSF cytology to 
determine response to treatment.2–8 However, no stand-
ardized assessment has been used consistently in these 
studies. Although radiographic assessments were often 
used in the above-mentioned RCT, radiographic response 
or impact on treatment varied or was not clearly defined. 
Currently, there is no well-defined effect of corticosteroids 
with respect to signs or symptoms of LM or evidence of 
diminution in LM-related MRI contrast enhancement in 
patients with nonhematologic cancers. Consequently, 
steroid dose is not considered in the proposed response 
criteria for solid tumor-related LM. Steroids are, however, 
recognized to be oncolytic in hematologic cancers, and 
consequently steroid dose is considered in the proposed 
response criteria for LM due to hematologic cancers. It 
is recognized that corticosteroids have utility in patients 
with brain metastases as well as in patients with intra-CSF 
treatment-related neurotoxicity—for example, treatment-
related chemical meningitis.
Neurological Assessment
The RANO LM working group in conjunction with the 
RANO Neurological Assessment working group has cre-
ated an instrument for assessing the neurological exam 
in patients with LM that will likely standardize response 
definitions in forthcoming LM trials and permit cross-
comparison among trials (Table  1).9 This instrument will 
require prospective validation, is considered a work in pro-
gress, and likely will require future revisions as additional 
knowledge and use are gained. The domains selected in 
the standardized neurological examination reflect primary 
sites of disease involvement by LM. Additionally the neu-
rological examination was designed to be simple so as to 
allow non-neurologists, including oncologists, nurse prac-
titioners, and physician assistants, to use it. Progressive 
disease in LM based on neurological assessment is defined 
by a change of 2 or more levels in a given domain (eg, gait) 
or alternatively by a change to level 3 (or level 2 in domains 
defined by only 3 levels) in any one domain (Table 1). It 
is acknowledged that attribution of disease progression 
can be challenging, since change in neurological function 
may also occur secondary to coexistent brain metastases, 
systemic disease progression, concurrent medications 
(including corticosteroids), or treatment-related toxicity. 
As the majority of neurological deficits due to LM are fixed 
and irreversible, it is anticipated that best response to treat-
ment usually will be stabilization of neurological function 
(ie, stable disease as assessed by neurological examina-
tion; Table 2). Transient neurological symptoms or deficits 
often are treatment related and do not represent progres-
sion of LM. Neurological examination is recommended to 
be determined at baseline in the conduct of a clinical trial 
and at the prespecified evaluation timepoints, preferably 
by a single examiner to minimize exam variability.
There is increasing evidence that patient-reported out-
comes (PROs) and performance status are prognostic 
indicators of both progression-free survival and overall 
survival in various cancers, including primary and meta-
static brain tumors.10–13 Cognitive and motor functioning 
as well as general symptoms are of prognostic importance 
in brain tumor patients.10,14 Though there are no published 
reports of PROs as an indicator of treatment response in 
LM patients, intuitively it is likely that quality-of-life meas-
ures, along with neurological examination, may also pro-
vide valuable insight into overall treatment response and 
tolerance. Suggested but not included as response crite-
ria for LM is incorporation of a symptom inventory such 
as the MD Anderson Cancer Center Symptom Inventory 
Brain Tumor Module (MDASI-BT) or the MD Anderson 
Cancer Center Symptom Inventory Spine Tumor Module 
(MDASI-SP), as currently there is no method to capture 
LM-relevant symptoms such as headache, nausea/vomit-
ing, or seizures. Obtaining baseline PRO measures utiliz-
ing tools such as the MDASI-BT or MDASI-SP helps define 
symptoms such as pain or incontinence, and a quality-of-
life measure such as the Functional Assessment of Cancer 
Therapy–Brain as an adjunct to the neurological examina-
tion likely would add value in overall assessment by meas-
uring the impact of the disease as well as treatment.
CSF Cytology/Flow Cytometry
CSF cytology is usually a qualitative analysis whereby 
results are reported as negative, atypical, suspicious, or 
positive.15–18 The majority of RCT have utilized a binary 
outcome measure, that is, either positive or negative such 
that an atypical report is considered negative and like-
wise a suspicious determination is considered positive. 
The RANO LM working group endorses this methodology. 
Furthermore, the committee is cognizant that quantita-
tive CSF cytology might theoretically be a more accurate 
descriptor of treatment response but is rarely performed in 
practice and may not be valid for various reasons, includ-
ing the vagaries of CSF flow dynamics. Therefore, at this 
time, response based on CSF cytology is considered when 
CSF converts from positive to negative (a complete CSF 
response) and in which a confirmatory determination is 
made from all sites (lumbar or ventricular) previously 
shown to be positive. In instances where a ventricular 
access device has been placed for intra-CSF chemotherapy 
administration, both sites (lumbar and ventricular) should 
be sampled to confirm a response. In addition, the dura-
tion of response is important. The working group believes a 
cytological response would be declared in instances where 
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Table 1 Neurological examination (adapted from RANO Neurological Assessment group)
Domain Level of Function Score Key Considerations
0 1 2 3
Gait Normal Abnormal but  
walks without 
assistance
Abnormal and 
requires assistance 
(companion, cane, 
walker, etc.)
Unable to walk 1.  Walking is ideally assessed by at least 
10 steps.
Strength Normal Movement present 
but decreased 
against resistance
Movement present 
but none against 
resistance
No movement 1. Each limb should be tested separately.
2.  Recommend assess proximal (above 
knee or elbow) and distal (below knee 
or elbow) major muscle groups.
3.  Score should reflect worst perform-
ing area.
4.  Patients with preexisting level 3 func-
tion in one major muscle group/limb 
at baseline can be scored based on 
assessment of other major muscle 
groups/limb.
Sensation Normal Decreased but 
aware of sensory 
modality
Unaware of sensory 
modality
--------- 1.  Recommend evaluating major body 
areas separately (face, limbs, and 
trunk).
2.  Score should reflect worst perform-
ing area.
3.  Sensory modality includes but is not 
limited to light touch, pinprick, tem-
perature, and proprioception.
4.  Patients with preexisting level 2 
function in one major body area at 
baseline can be scored based on 
assessment of other major body 
areas.
Vision Normal Partial monocular 
visual loss
Complete monocular 
visual loss
Bilateral visual 
loss
1.  Patients who require corrective lenses 
should be evaluated while wearing 
corrective lenses.
2.  Each eye should be evaluated, and 
score should reflect worst performing 
eye.
Eye 
movements
Normal Abnormality noted 
in 1 direction of  
gaze
Abnormality noted 
in more than 1 gaze 
direction, but not all
Unable to move 
the eye in any 
gaze direction
1. Test eye movements for each eye 
individually.
2. The score will reflect the worst per-
forming eye (ie, the highest score).
Facial 
strength
Normal Mild facial weakness 
(nasolabial 
fold flattening, 
asymmetric smile, 
decreased forehead 
contraction, or 
partial eye closure)
Severe facial weak-
ness (severe nasola-
bial fold flattening, 
asymmetric smile with 
limited or no move-
ment of face, incom-
plete eye closure, or 
labial incompetence
Bilateral facial 
weakness
1  Weakness includes nasolabial fold 
flattening, asymmetric smile, and dif-
ficulty elevating eyebrow.
Hearing Normal Impaired but 
residual serviceable 
hearing
Absent unilateral 
hearing
Bilateral hearing 
loss
1.  Each ear should be evaluated and 
score should reflect worst perform-
ing ear.
Swallowing Normal Impaired but not 
requiring change 
in diet formulation, 
not aspirating by 
bedside testing
Unable to swallow 
without risk of aspira-
tion by bedside testing
----------- 1.  Bedside testing comprising a swallow 
test with a small glass of water.
Level of con-
sciousness
Normal Drowsy (easily 
arousable & 
responsive)
Somnolent (difficult 
to arouse & poorly 
responsive)
Coma (una-
rousable & 
unresponsive)
Behavior Normal Mild/moderate 
alteration
Severe alteration --------- 1.  Alteration includes but is not lim-
ited to apathy, disinhibition, and 
confusion.
3.  Consider subclinical seizures for 
significant alteration.
Other Normal Occasional or mild Persistent, moderate 
to severe
------------
Legend: “Other”:  Neurological findings not otherwise defined in the current examination, for example ataxia.
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the CSF is cleared of identifiable tumor cells from all sites 
of identified disease and maintains that status for 4 weeks, 
a time period felt to be clinically relevant. Nonetheless, 
the working group recognizes the limitations of cytologi-
cal response, as the sensitivity of CSF cytology is poor and 
the potential of making a declaration of “response” even 
though tumor cells are still present in CSF but not found 
(ie, a false negative) may be as high as 50%.15 Importantly, 
results of CSF cytology are dependent upon a number of 
factors, including (i) whether sufficient volume (a mini-
mum of 10 mL) is obtained at time of acquisition, (ii) a site 
is selected as close to symptomatic or radiographically 
proven disease as possible to obtain CSF (for example, 
patients with primarily intracranial LM more often have 
positive CSF cytology from an intracranial site compared 
with lumbar CSF sampling), and (iii) rapid processing by 
pathology occurs after obtaining CSF for analysis.16,19 
Designation as progressive or refractory disease based 
upon CSF assessment does not require a confirmatory 
CSF analysis following a treatment course which fails to 
show a complete response. Progressive disease is defined 
by either conversion of negative to positive CSF cytology 
or failure to convert positive cytology to negative follow-
ing induction (duration may vary according to treatment 
and trial design) [refractory disease] (Table 3). A practical 
issue with the declaration of refractory disease in a patient 
with persistently positive CSF cytology after induction 
therapy is seen in the instance wherein patients are oth-
erwise clinically and radiographically stable or improved. 
The working group was unable to achieve a consensus in 
this clinical scenario notwithstanding evidence from RCT 
that suggests survival in patients with persistently positive 
CSF cytology following induction therapy with intra-CSF 
chemotherapy is abbreviated relative to patients in whom 
CSF conversion is seen. However, prior studies have not 
defined response parameters for clinical or radiological 
disease progression and as such, interpreting the meaning 
of positive CSF cytology in an otherwise stable patient is 
difficult. Currently 2 clinical trials in France of women with 
breast cancer and LM have elected not to consider CSF 
cytology as a primary response criterion and when com-
pleted will clarify the utility of CSF cytology in this solid 
tumor-related LM.
CSF FC in contrast is a quantitative analysis that uti-
lizes a binary outcome (ie, positive or negative, like CSF 
cytology).20–30 This method has been evaluated mainly 
for hematologic LM and is used as an additional (or 
replacement) method to cytology.20 An advantage of FC 
is that it relies on automation, thus allowing an objective 
determination of CSF tumor burden as contrasted with 
the subjective morphology interpretation by CSF cytol-
ogy.21 The sensitivity of FC permits detection of very low 
CSF disease burden, as low as 0.1% of the total CSF cell 
count.24 In patients with lymphoma, positive FC even in 
the presence of negative CSF cytology has been associ-
ated with increased risk of CNS relapse, suggesting that 
even a low burden of disease is clinically relevant.22,25,26 
False positive results have been reported in patients 
with inflammatory diseases and without known hemato-
logic malignancy.27 Therefore, in patients without known 
hematologic malignancy, FC results should be interpreted 
with caution.18,22 A  limitation of CSF FC is that cancer 
cells deteriorate rapidly after removal, especially when 
centrifuged many times.23 However, with the use of a 
stabilizing medium, FC may be reliably performed up to 
18 hours after collection of the CSF.29 Nevertheless, this 
technique requires standardization, with special attention 
given to speed of processing, adequate use of centrifu-
gation, and buffer use to permit cell viability as well as 
optimal use of markers.23,30 Response to treatment would 
be assessed similar to that of CSF cytology. Despite the 
greater sensitivity of FC, very infrequently FC remains 
negative in a patient with positive cytology; therefore, the 
two techniques should be used in parallel in patients with 
hematologic malignancies.20,25 CSF FC as used to assess 
LM in patients with hematologic cancers, if persistently 
positive, constitutes refractory disease irrespective of 
neurological or radiological determination dissimilar to 
the definition of progressive disease when utilizing CSF 
cytology (Table 3).
Table 2. MRI parameters in leptomeningeal disease
MRI prerequisites
1.5T and 3T MR scanners only
Use of same MRI at baseline and follow-up
MRI to be performed prior to lumbar puncture
Recommended MRI sequences
Brain
Volumetric 3D T1 (magnetization-prepared rapid acquisition with gradient echo [MPRAGE] or spoiled gradient [SPGR]) postcontrast 
image with isotropic 1-mm voxels to permit reformatting in 3 planes (axial, coronal, and sagittal)
Reformatted slice thickness 3 mm to obtain good signal to noise ration and manageable number of slices for full brain coverage
IV contrast dose = 0.1 mmol/kg of gadolinium-based agent.
Spine
Volumetric 3D T1 (MPRAGE or SPGR) postcontrast image in sagittal plane with isotropic 1 mm voxels to permit reformatting in 3 
planes (axial, coronal, and sagittal) with a 2‒3 mm reformatted slice thickness without gap.
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CSF assessment (CSF cytology in all cancers and com-
bined CSF cytology and FC in hematologic malignancies) 
is suggested at baseline and repeated with each cycle 
of LM-directed therapy (once weekly or twice monthly 
during induction, monthly or bimonthly during mainte-
nance therapy). The addition of CSF protein, glucose, and 
cell count is not recommended in assessing response to 
treatment in clinical trials, as these adjunctive measures 
rarely reflect disease response but may be useful in other 
clinical contexts such as treatment-related toxicity or 
CSF cytology‒negative LM. In the future, advancement 
in methodologies for the identification of CSF circulat-
ing tumor cells—for example, utilizing rare cell capture 
technology or CellSearch—will potentially be more sensi-
tive, and if validated, such methods might warrant revi-
sions in the current recommendations.31–35 Similarly, 
identification of new soluble CSF biomarkers might, if 
validated, alter current response definitions.36–41 The use 
of novel biomarkers such as tumor antigens, signaling 
pathway molecules involved in extravasation, adhesion, 
migration, angiogenesis, and chemokines are currently 
being evaluated as to a role for improved detection and 
treatment of LM, but none of these assays have been 
validated.36–41
Neuroimaging Assessment
The most challenging element of response assessment 
in LM is the neuroimaging evaluation. The question of 
whether MRI assessment can replace CSF analysis has 
never been addressed, primarily as (i) there are no criteria 
for adjudicating response by MRI in LM disease, (ii) MRI is 
underused in a standardized manner in RCT of LM disease, 
and (iii) perhaps most importantly, normal MRI assessment 
in patients with LM disease is not infrequent. MRI assess-
ment of the neuraxis is useful only when positive and as 
such in patients with negative MRI, alternative methods of 
response are required.
MRI abnormalities of LM include enhancement of the 
leptomeninges of the brain or spinal cord identified as 
Table 3. Scorecard for radiographic assessment in leptomeningeal metastases
MRI Findings Present (1) or Absent (0) or 
Non-evaluable (NE)
Dimensions Of Measurable Nodules 
Defined as
>5 x 10 mm (orthogonal diameters)
Change from  
Previous MRI
(−3 to +3)
BRAIN
Nodules (subarachnoid or 
ventricular)
Leptomeningeal enhancement*
Cranial nerve enhancement
Hydrocephalus^
Parenchymal (brain metastases)^
SPINE
Nodules (subarachnoid)
Leptomeningeal enhancement
Nerve root enhancement
Parenchymal(intramedullary 
metastases)^
Epidural metastasis ^
TOTAL SCORE
Legend:
*Leptomeningeal enhancement may include pia, cerebellar folia, ventricular ependyma or cerebral sulci.
^Both hydrocephalus and parenchymal metastases, either brain or spine, are noted as present or absent but not used for LM response determina-
tion.
Column 2: scored as 1 (present) or 0- (absent) or non-evaluable (NE). A maximum of 5 radiographic target lesions are selected from baseline imaging 
to score on follow-up.
Column 3: scores each measurable lesion (at least 5 × 10 mm) excluding parenchymal as 1 (present with maximum orthogonal diameters) or 0 (ab-
sent).
Column 4: change from baseline or prior image scored as same (0), probable improvement (+1), definite improvement (+2), no evidence of disease 
(+3) or probable worsening (−1), definite worsening (−2), new site(s) of disease (−3). Measurable nodules defined as ≥5 × 10 mm are scored as same 
(0), resolved (no evidence of disease, complete response), definitely better (+2; partial response) [decrease by >50% in the summed product of 
orthogonal diameters], definite worsening (−2; progressive disease) [increase by >25% in the summed product of orthogonal diameters]. A compos-
ite score (total score) is calculated and compared with the baseline total score. A 25% worsening in the current score relative to baseline defines 
radiographic progressive disease. A 50% improvement in the current score defines a radiographic partial response. Resolution of all baseline radio-
graphic abnormalities defines a complete response. All other situations define stable disease.
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enhancement of the cranial nerves and spinal nerve 
roots, brain surface, cerebellar foliae, and within cerebral 
sulci.42–49 Pathological enhancement may be nodular, 
linear, or curvilinear as well as focal or diffuse. Because 
radiographic features typical of LM are generally small in 
volume and complex in geometry, current MRI technology 
does not permit quantitative assessment. 31–33 Nodules in 
the subarachnoid space or ventricles are often difficult to 
measure because they are small (often <5 mm), adjoined 
by linear enhancement, and subject to inter-MRI variabil-
ity due to slice positioning and contrast conspicuity. The 
working group recommends that nodular disease that is 
≥5 × 10 mm in orthogonal diameters be defined as meas-
urable and be serially assessed in follow-up imaging. 
Synchronous or metachronous presence of parenchymal 
brain or spine metastases should be considered separately 
from response definitions for LM and would be adjudi-
cated independently as previously described.50
The working group recommends contrast MRI of brain 
and entire spine at baseline and at prespecified times 
thereafter, such as following completion of induction ther-
apy. Other neuroimaging modalities (MR spectroscopy, MR 
perfusion, and PET) do not currently have a defined role in 
the assessment of LM. Radioisotope cisternography, also 
referred to as CSF flow studies, is recommended only in 
patients considered for intra-CSF therapy, as disruption of 
CSF movement impacts intra-CSF drug delivery.51–55
Suggested imaging requirements for MRI are given in 
Table 2. Interpretation of MRI emphasizes areas of patho-
logical gadolinium enhancement consistent with LM. 
Presence or absence of hydrocephalus should be noted 
and contribute to response assessment. However, changes 
in hydrocephalus volume are not part of the proposed 
system for assessment of LM response. It is proposed 
that 6 regions (outlined in Table 3) of the CNS be assessed 
for pathological contrast enhancement on MRI consist-
ent with LM, with findings for each region documented 
at baseline as present (abnormality present), absent (no 
abnormality; normal), or non-evaluable (NE). In follow-up, 
features in these regions (or new regions of involvement) 
should be assessed as completely resolved (+3), definitely 
improved (+2), possibly improved (+1), unchanged (0), 
possibly worse (−1), definitely worse (−2), or new site of 
disease (−3), as per Table 3. A scheme for combining these 
assessments to determine response to treatment is given 
in Tables 3 and 4. Assessment should emphasize changes 
in size and extent but not in intensity of enhancement. 
Subarachnoid or ventricular nodules with nonmeasurable 
dimensions should be noted and considered in assessing 
change as with enhancement. Nodules that are measurable 
are defined as definitely worse if >25% of the baseline sum 
of the product of their orthogonal diameters. Similarly, if 
the summed product of orthogonal diameters of the tumor 
nodules decreases >50%, then response would be graded 
as definitely improved (ie, partial response). Nodules 
that disappear on treatment would be graded as a com-
plete response for this defined target lesion only. All other 
parameters of measurable nodules would be rated as sta-
ble. Overall radiographic response is determined by the 
composite score for both measurable and nonmeasurable 
Table 4. Response determination in leptomeningeal metastases
Assessment Response Progressive or refractory disease Stable Disease
Neurological 
Examination  
Defined  
Progression
CSF Defined  
Disease  
Progression
Radiologic  
Defined Disease 
Progression
Symptoms^
Neurological 
Exam
Improved Worse Stable Stable Stable Stable
CSF cytology
(all cancers)
Negative Negative Positive (lack 
consensus)
Negative Negative Negative or positive 
(solid tumors only)
CSF flow 
cytometry
(in hematologic 
cancers only)
Negative Negative Positive
(lack consensus)
Negative Negative Negative or positive
CNS
imaging
Definite 
improvement
Stable Stable Definite  
worsening
Stable Stable or equivocally 
worsening or improved
Steroid dose
(in hematologic 
cancers only)
None or 
decreased
Stable or  
increased
Stable or  
increased
Stable or  
increased
Stable Stable or decreased
Symptom 
assessment
Improved Worse or stable Worse or stable Worse or stable Worse Stable
Legend:
CSF cytology negative Defined as either true negative or atypical
CSF cytology positive Defined as true positive or suspicious
Stable Defined as stable or indeterminate
Symptoms^Stable; no change (−1 to +1 in symptom inventory
Worse; −2 to −3 in symptom inventory
Improved; +2 to +3 in symptom inventory
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lesions. Up to 5 target radiographic lesions (either measur-
able or nonmeasurable) are selected at baseline and fol-
lowed serially to permit response assessment (Table  3). 
Radiographic response may reflect treatment with either 
chemotherapy (systemic or intra-CSF) or involved-field 
radiotherapy. Fluid attenuated inversion recovery (FLAIR) 
and T2 abnormalities without enhancement are not assess-
able as features of LM and may result in false positive 
interpretation. Changes in parenchymal brain or spine 
metastases should be noted but are not considered in the 
radiological assessment of LM.
Several caveats regarding this proposed radiographic 
assessment of LM are to be noted. The conspicuity of 
enhancing features may vary with gadolinium formulation 
and dose, rapidity of infusion, and elapsed time between 
infusion and image acquisition. Image raters are encour-
aged to note the prominence of enhancement of normal 
enhancing features (dura, falx, choroid plexus, vessels, 
and leptomeninges) and account for these normal features 
when assessing change on successive scans. Raters should 
be especially circumspect about interpreting response of 
leptomeningeal contrast enhancement without nodularity. 
Care should be taken to avoid considering enhancement 
due to LM which results from intra-CSF treatment, post-
surgical enhancement of dura/arachnoid, skull metasta-
ses, intracranial hypotension (especially after a lumbar 
puncture or placement of a ventriculoperitoneal shunt), 
blood vessels, etc. For nodules that are not measurable as 
defined above, raters are advised to be conservative about 
interpreting possible changes that may be due to different 
slice spacing.
Clinical, MRI, and CSF assessments should ideally be 
performed at the same timepoints, but with MRI preced-
ing lumbar puncture. MRI should be avoided shortly after 
lumbar puncture to minimize false positive meningeal 
enhancement.48,56
The recommendations for neuroimaging assessment of 
LM have not been validated and should be regarded as a 
work in progress. Experience with this proposed strategy 
and advances in technology—for example, postcontrast 
T2-FLAIR MRI—are likely to refine and improve neuroim-
aging assessment of LM in the future.57–59
Conclusions
Response evaluation in LM is a challenging subject in 
neuro-oncology in that there exists little to no consen-
sus. The RANO LM working group proposes a composite 
response assessment wherein evaluation of the neuro-
logical examination is performed using a newly proposed 
standardized instrument, CSF cytology/FC evaluation, 
along with a composite score of MRI of the CNS, which 
also is a newly proposed instrument. These 3 elements 
(neurological examination, presence or absence of CSF 
circulating tumor cells, and neuraxis imaging) are used 
together and at each response assessment. While the cur-
rent proposed response criteria for LM does not account 
for all aspects of this metastatic complication (for example, 
response of brain metastases or systemic cancer), it does 
provide a framework for use in clinical trials. The novel 
response instruments proposed herein require validation 
and likely modification over time to account for changes in 
CSF and CNS imaging diagnostics as they pertain to LM. 
Importantly in the current proposal, progressive disease 
is defined in 2 specific contexts: worsening neurological 
examination due to LM (sufficient in isolation), persistently 
positive CSF cytology or FC (insufficient in isolation), or 
worsening neuroradiographic assessment (sufficient in 
isolation) (Table 4). The latter category of radiological pro-
gressive LM (Table 2) is like the neurological examination: 
a composite score and a newly proposed instrument that 
will require validation and likely modification with use 
and new methodology. The inclusion of an assessment by 
a symptom burden instrument as shown in Table 3 is pro-
posed as having clinical relevance in that elements of LM 
that are defined only by symptoms (headache, seizures) 
are not included by standard response tools.
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